<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Relative risk compared with absolute risk for venous thromboembolism by characteristic</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Relative risk compared with absolute risk for venous thromboembolism by characteristic</h1>
<div class="graphic"><div class="figure"><div class="ttl">Relative risk compared with absolute risk for venous thromboembolism by characteristic</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Variable</td> <td class="subtitle1">Relative risk compared with nonpregnant women without the risk factor</td> <td class="subtitle1">Absolute risk</td> </tr> <tr class="divider_bottom"> <td>Nonpregnant, not taking hormones</td> <td>1.0</td> <td>VTE: 1 to 5/10,000 <span style="white-space: nowrap;">woman-years<sup>[1]</sup></span></td> </tr> <tr class="divider_bottom"> <td>Pregnancy</td> <td>4.29 (95% CI 3.49-5.22; p&lt;0.001) compared with nonpregnant <span style="white-space: nowrap;">women<sup>[4]</sup></span></td> <td> <p>VTE: 5 to 20/10,000 <span style="white-space: nowrap;">woman-years<sup>[1]</sup></span></p> PE: 1/10,000 woman-years </td> </tr> <tr class="divider_bottom"> <td>Postpartum</td> <td>4.29 (95% CI 3.49-5.22; p&lt;0.001) compared with nonpregnant <span style="white-space: nowrap;">women<sup>[4]</sup></span></td> <td> <p>VTE: 40 to 65/10,000 <span style="white-space: nowrap;">woman-years<sup>[1]</sup></span></p> PE: 16 per 10,000 woman-years </td> </tr> <tr> <td class="divider_bottom" rowspan="7">Progestin type</td> <td>RR of <span style="white-space: nowrap;">VTE:<sup>[2,3]</sup></span></td> <td> </td> </tr> <tr> <td class="indent1">Non-use versus first-generation (norethindrone COC) users: 3.2 (95% CI 2.0-5.1)</td> <td> </td> </tr> <tr> <td class="indent1">Non-use versus second-generation (levonorgestrel COC) users: 2.8 (95% CI 2.0-4.1)</td> <td> </td> </tr> <tr> <td class="indent1">Non-use versus third-generation (desogestrel COC) users: 3.8 (95% CI 2.7-5.4)</td> <td> </td> </tr> <tr> <td class="indent1">Second versus first generation: 0.9 (95% CI 0.6-1.4)</td> <td> </td> </tr> <tr> <td class="indent1">Third versus first generation: 1.2 (95% CI 0.8-1.9)</td> <td> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Third versus second generation: 1.3 (95% CI 1.0-1.8)</td> <td> </td> </tr> <tr> <td class="divider_bottom" rowspan="3">Estrogen dose</td> <td>20 mcg ethinyl estradiol with levonorgestrel versus non-use: 2.2 (95% CI 1.3-3.6)</td> <td> </td> </tr> <tr> <td>30 mcg ethinyl estradiol with levonorgestrel versus 20 mcg ethinyl estradiol with levonorgestrel: 1.1 (95% CI 0.7-1.7)</td> <td> </td> </tr> <tr class="divider_bottom"> <td>50 mcg ethinyl estradiol with levonorgestrel versus 20 mcg ethinyl estradiol with levonorgestrel: 2.3 (95% CI <span style="white-space: nowrap;">1.3-4.2)<sup>[2,3]</sup></span></td> <td> </td> </tr> <tr> <td rowspan="2">Thrombophilias</td> <td>Factor V Leiden: 2.6 no OC, 64.7 first/second generation, 29.6 third generation</td> <td> </td> </tr> <tr> <td>Other heritable thrombophilia: 2.6 no OC, 63.3 first/second generation; 52.5 third <span style="white-space: nowrap;">generation<sup>[4]</sup></span></td> <td> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Although drospirenone is not listed, limited data suggest combined oral contraceptive pills containing drospirenone may be associated with a higher relative risk of VTE compared with second-generation (rate ratio 1.65, 95% CI 1.02-2.65) and third-generation (rate ratio 1.43, 95% CI 1.15-1.78) combined oral contraceptive <font style="WHITE-SPACE: nowrap">pills.<sup>[6]</sup></font></div><div class="graphic_footnotes">VTE: venous thromboembolism; CI: confidence interval; PE: pulmonary embolism; RR: relative risk; COC: combined oral contraceptives; OC: oral contraceptives.</div><div class="graphic_reference">References: 

<ol>
<li>Committee on Gynecologic Practice. ACOG Committee Opinion Number 540: Risk of venous thromboembolism among users of drospirenone containing oral contraceptive pills. Obstet Gynecol 2012; 120:1239.</li>
<li>Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network metaanalysis. BMJ 2013; 347:f5298.</li>
<li>de Bastos M, Stegeman BH, Rosendaal FR, et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014; :CD010813.</li>
<li>Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005; 143:697.</li>
<li>Andersen BS, Olsen J, Nielsen GL, et al. Third generation oral contraceptives and heritable thrombophilia as risk factors of non-fatal venous thromboembolism. Thromb Haemost 1998; 79:28.</li>
<li>Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011; 183:E1319.</li></ol>Reproduced from: Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril 2017; 107:43. Table used with the permission of Elsevier Inc.</div><div id="graphicVersion">Graphic 121107 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
